Epidemiology and economic burden of Puumala virus infection in Styria, Austria, 2003 to 2024

Clicks: 21
ID: 329902
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #160 of 318 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Hantavirus infections cause hemorrhagic fever with renal syndrome and impose a potential burden on healthcare systems. However, comprehensive economic data remain scarce. We quantified the inpatient economic burden of hospitalized patients with Puumala virus (PUUV) infections in Styria, Austria´s primary endemic region, to identify hospitalization costs and early admission predictors of costs. Methods This retrospective cost-of-illness study analyzed 1,049 serologically confirmed PUUV hospitalizations across 20 public hospitals in Styria, Austria between September 2003 and March 2024. Costs were estimated using the Austrian performance-oriented hospital financing (LKF) diagnosis-related-group-system, standardized to 2024-equivalent Euros using consumer-price-index deflation. Admission predictors of cost were assessed using multivariable γ-generalized-linear-modeling with multiple imputation. Temporal trends in length of stay were analyzed using weighted segmented linear regression. Results Cumulative inpatient cost was approximately €10.3 million (mean per-case: €9,788) for the entire study period of 21 years. Three epidemic years (2012, 2019, 2021) accounted for 53.6% of cases and over €5.2 million in expenditure, with peak annual costs reaching €1.93 million (0.274% of total Styrian inpatient expenditure) in 2012. Prolonged activated partial thromboplastin time (aPTT; cost-ratio 1.024 per second, 95% CI 1.019–1.030) and older age (CR 1.004 per year, 95%-CI 1.001–1.008) were independent admission-level predictors of higher cost. Median hospital length of stay declined by approximately 50% over the study period. Conclusions PUUV hospitalizations impose a sharply episodic but recurrent economic burden on regional healthcare systems. Admission aPTT and age independently predicted cost, but clinical outcomes were not modelled and these variables do not constitute a triage tool. Epidemic preparedness strategies are warranted.
Reference Key
openalex_W7214459379 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Stefan Hatzl, Christina Geiger, Lisa Kriegl, Markus Keldorfer, Gernot Schilcher, Florian Krammer, Robert Krause
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag607
URL
https://doi.org/10.1093/ofid/ofag607
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.